Emergent BioSolutions’ C.E.O. announced several executive changes but vigorously defended the company, which is on track for record revenues. New York Times By BY SHERYL GAY STOLBERG AND CHRIS HAMBY from NYT U.S. https://ift.tt/3vvCWfL
Coronavirus (2019-nCoV), Vaccination and Immunization, Factories and Manufacturing, Government Contracts and Procurement, Drugs (Pharmaceuticals), Regulation and Deregulation of Industry
Comments
Post a Comment